Hallie E. Kuhn, who serves as Executive Vice President of Capital Markets and Co-Lead of Life Science for Alexandria Real Estate Equities, Inc. (NASDAQ: ARE), executed a personal sale of company stock on April 17, 2026. The transaction involved 536 shares sold at $48.20 per share, producing gross proceeds of $25,835.
Following the sale, Ms. Kuhn directly retains ownership of 48,301 shares of Alexandria common stock. At the time of the report, the companys shares were trading near $47.81. Market movements show the stock rebounded 7.9% over the most recent week after experiencing a 34% decline over the prior six months.
Third-party valuation commentary included in the report indicates that, according to InvestingPro analysis, the stock appears undervalued at current levels. The health care real estate investment trust is noted as carrying a dividend yield of 5.88%.
Alexandria also announced a quarterly cash dividend of $0.72 per common share for the first quarter of 2026, with the dividend payable in April.
In related corporate activity covered alongside the insider transaction, Aecon Group Inc. reported several developments. Aecon has secured a material contract as part of a joint venture for the Howard A. Hanson Dam Additional Water Storage Fish Passage Facility project in Washington State. The total value of the contract is US$691 million, with Aecons share amounting to approximately US$276 million. The company said this amount will be recorded to its Construction segment backlog in the first quarter of 2026.
Aecon further disclosed the acquisition of Duna Services, LLC and its subsidiaries for $60 million, with potential contingent payments. The purchase is being financed through a standalone committed revolving credit facility.
On governance, Aecon announced the appointment of Jeff Lyash to its Board of Directors. Mr. Lyash is expected to stand for election at the companys Annual General Meeting in June 2026.
On the analyst front, BMO Capital adjusted its view of Alexandria Real Estate Equities, downgrading the stock from Outperform to Market Perform. BMO set a price target of $52.00, citing its assessment based on the companys net asset value and discounted cash flow estimates.
No additional commentary or forward-looking statements were included beyond the transactions, dividend declaration, Aecon developments, and the BMO Capital rating change.